Concepedia

Single‐ and Multiple‐Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid

Shawn Flanagan, Edward Fang, Kelly A. Muñoz, Sonia L. Minassian, Philippe Prokocimer

Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · 2014 · 85 citations · 11 references

DOIFull text

Open access

Abstract

These results from a population of healthy volunteers support once/day dosing of tedizolid phosphate 200 mg with both the oral and IV formulations, without the need for dose adjustment when switching administration routes.

References

11

Survey of Infections Due to<i>Staphylococcus</i>Species: Frequency of Occurrence and Antimicrobial Susceptibility of Isolates Collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997–1999

Daniel J. Diekema, Michael A. Pfaller, Franz‐Josef Schmitz et al. · Clinical Infectious Diseases · 2001 · 1.4K citations

, , +20

Tedizolid Phosphate vs Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections

Philippe Prokocimer, Carisa De Anda, Edward Fang et al. · JAMA · 2013 · 352 citations

<i>Staphylococcus aureus</i>–associated Skin and Soft Tissue Infections in Ambulatory Care

Linda F. McCaig, L. Clifford McDonald, S. K. Mandal et al. · Emerging infectious diseases · 2006 · 303 citations · Full text

, , +16

Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial

Gregory J. Moran, Edward Fang, G. Ralph Corey et al. · The Lancet Infectious Diseases · 2014 · 301 citations

, , +8

Trends in the Incidence of Methicillin‐Resistant<i>Staphylococcus aureus</i>Infection in Children’s Hospitals in the United States

Jeffrey S. Gerber, Susan Coffin, Sarah Smathers et al. · Clinical Infectious Diseases · 2009 · 185 citations · Full text